Advaxis and MedImmune Partner on Immuno-Oncology Combination Clinical Trial
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Aegis Capital Affirms Advaxis (ADXS) at 'Buy'; MedImmune Agreement Could Open Doors to More Licensing
July 22, 2014 11:12 AM EDTAegis Capital affirms Advaxis, Inc. (Nasdaq: ADXS) at Buy with a target price of $15 following news that the company entered into a clinical trial collaboration with MedImmune, the global biologics research and development arm of AstraZeneca (NYSE: AZN).
Analyst Ram Selvaraju said, In our view, the partnership with... More
